|
Alveolar rhabdomyosarcoma
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Clonality and evolutionary history of rhabdomyosarcoma.
|
25768946 |
2015 |
|
Insulin Resistance
|
0.200 |
Biomarker
|
phenotype |
RGD |
The severe insulin resistance predominantly in epididymal adipose tissue of WOKW rats is associated with a 10-fold decrease in adipocyte adiponectin gene expression, decreased Ppar gamma, but increased Foxo1 gene expression compared to DA rats.
|
16041833 |
2006 |
|
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1
|
0.200 |
Therapeutic
|
disease |
RGD |
Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.
|
30186875 |
2018 |
|
LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.
|
30186875 |
2018 |
|
FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats.
|
30186875 |
2018 |
|
Alveolar rhabdomyosarcoma
|
0.800 |
FusionGene
|
disease |
ORPHANET |
|
|
|
|
Alveolar rhabdomyosarcoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
|
Somatic mutation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Alveolar rhabdomyosarcoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
FOXO1 break-apart by FISH was positive in 4 of 6 (66%) ARMS and 2 of 5 (40%) RMS-NOS cases.
|
18303411 |
2008 |
|
Alveolar rhabdomyosarcoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
In this paper, we report that FOXO1a is not expressed in primary ARMS tumors or ARMS-derived tumor cell lines and that restoration of FOXO1a expression in ARMS cells is sufficient to induce cell cycle arrest and apoptosis.
|
16157701 |
2005 |
|
Alveolar rhabdomyosarcoma
|
0.800 |
Biomarker
|
disease |
LHGDN |
Solid alveolar rhabdomyosarcoma originating from the urinary bladder in an adult. Diagnostic value of molecular genetics.
|
15140004 |
2004 |
|
Alveolar rhabdomyosarcoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
PAX3-FKHR and PAX7-FKHR fusion transcripts were detected in 55% and 22% of ARMS patients, respectively; 23% were fusion-negative.
|
12039929 |
2002 |
|
Alveolar rhabdomyosarcoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
PAX3-FKHR fusion transcripts were positive in 3/7 and PAX 7-FKHR fusion transcripts were positive in 2/7 of ARMS patients, respectively, and were all negative in ERMS and Control tumors.
|
17285543 |
2007 |
|
Alveolar rhabdomyosarcoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
These studies reveal a prominent role for PAX3-FKHR in disrupting Pax3 functions and in deregulating skeletal muscle development, suggesting that this fusion protein plays a critical role in the pathogenesis of alveolar RMS by influencing the commitment and differentiation of the myogenic cell lineage.
|
16952014 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.350 |
PosttranslationalModification
|
disease |
LHGDN |
In conclusion, the constitutive phosphorylation of FKHR was observed in the majority of AML, and the detection of phospho-FKHR might provide a new tool for identifying AML patients with an unfavorable outcome.
|
12921955 |
2003 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation.
|
15692560 |
2005 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer.
|
16849544 |
2006 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
LHGDN |
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.
|
12482965 |
2003 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
LHGDN |
Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.
|
17597184 |
2007 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells.
|
14726521 |
2004 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
|
18988640 |
2009 |
|
Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
This prompted us to explore the effect of expressing PAX3-FKHR in more relevant cells, specifically primary human skeletal muscle cells because these cells can be converted to a tumorigenic state that mimics rhabdomyosarcoma.
|
17638879 |
2007 |
|
Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, these studies reveal that PAX3, PAX7 and their fusions with FKHR are each expressed in RMS tumors as a consistent mixture of functionally distinct isoforms.
|
15688409 |
2005 |
|
Embryonal Rhabdomyosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
To explore molecular pathways altered by this oncoprotein, we generated an inducible form by fusing PAX3-FKHR to a modified estrogen receptor ligand-binding domain and expressed this construct in the RD embryonal rhabdomyosarcoma cell line.
|
15184910 |
2004 |
|
Embryonal Rhabdomyosarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
PAX3-FKHR fusion transcripts were positive in 3/7 and PAX 7-FKHR fusion transcripts were positive in 2/7 of ARMS patients, respectively, and were all negative in ERMS and Control tumors.
|
17285543 |
2007 |